Lineage Cell Therapeutics, Inc.LCTXNYSE

Revenue (LTM)

$15M

+53.2% YoY

Net Income (LTM)

$-64M

-241.4% YoY

Free Cash Flow

$-19M

Revenue CAGR (5Y)

+79.9%

Marginsimproving

FCF($0.0B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	4	15↑277.4%	9↓39.2%	9↑6.2%	15↑53.2%
Gross Profit	2	14↑465.8%	8↓40.8%	9↑10.8%	14↑49.6%
Operating Income	-49	-23↑54.2%	-25↓9.8%	-21↑13.2%	-22↓1.4%
Net Income	-43	-26↑38.9%	-21↑18.2%	-19↑13.4%	-64↓241.4%
EBITDA	-48	-22↑54.9%	-24↓10.3%	-21↑13.2%	-21↓1.0%
EPS Diluted	-0.26	-0.15↑42.3%	-0.12↑20.0%	-0.09↑22.5%	-0.28↓201.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	56	11↓79.6%	35↑212.1%	46↑29.2%	41↓10.9%
Total Current Assets	112	60↓46.2%	38↓35.9%	51↑32.7%	59↑16.0%
Total Assets	175	124↓29.2%	101↓18.3%	113↑12.1%	113↓0.6%
Total Current Liabilities	47	19↓59.7%	18↓5.4%	14↓22.2%	11↓18.7%
Total Liabilities	84	52↓38.2%	39↓24.6%	36↓7.2%	69↑91.2%
Total Equity	92	73↓20.5%	63↓13.5%	78↑23.6%	45↓43.2%
Total Debt	3	4↑39.0%	3↓24.2%	3↓14.8%	2↓3.8%
Net Debt	-53	-7↑85.9%	-32↓335.6%	-43↓33.2%	-38↑11.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-24	1↑104.5%	-29↓2797.5%	-23↑19.2%	-19↑18.1%
Capital Expenditure	-0	-0↓16.7%	-1↓63.2%	-1↑16.2%	-1↑7.6%
Free Cash Flow	-24	1↑102.7%	-29↓4626.3%	-24↑19.1%	-19↑17.8%
Stock-Based Comp	4	4↑21.8%	5↑8.2%	5↑9.4%	5↓6.4%
Net Change in Cash	23	-44↓292.0%	24↑154.3%	10↓56.9%	-5↓148.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance